OrbiMed

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Shenluo Medical manufactures functional neural implantable medical devices.

Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics to target high-value, validated oncogenic drivers. It employs structure-guided drug discovery and advanced computational chemistry to create small-molecule therapies that selectively address oncogenic alterations, with the aim of improving patient outcomes in cancer.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

BlossomHill Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for oncology and autoimmune diseases. It specializes in small molecule drug discovery, leveraging advanced drug design expertise and precision medicine approaches.

Terremoto Biosciences is a biotechnology company that develops innovative drug delivery systems. Its platform enables the creation of optimized small-molecule medicines, aiming to enhance therapeutic benefits and potentially cure diseases.

Angitia Biopharmaceuticals is a global clinical-stage biotechnology company focused on discovering and developing therapeutics for musculoskeletal diseases, specifically targeting bone, muscle, and joint conditions. Through its research and development activities, it aims to deliver breakthrough therapies that address unmet needs and improve outcomes for patients with severe musculoskeletal disorders.

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.

Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Founded in 2020, Evozyne is a biotechnology company specializing in protein design using its data-driven evolution-based molecular engineering platform. Headquartered in Chicago, Illinois, the company focuses on therapeutic discovery and drug development to create novel proteins with advanced functionality.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Upstream Bio is a clinical-stage biotechnology company focused on developing antibody therapies for severe respiratory disorders. Its lead product, Verekitug, targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine involved in inflammatory responses.

Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat life-threatening diseases. It seeks to eliminate dependency on donor or patient cells for blood stem cell transplants, leveraging a platform technology that generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free, providing patients with rapid and broad access to durable therapies.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

ArriVent is a biopharmaceutical company focused on developing innovative medicines to treat currently untreatable cancers. It aims to advance its lead candidate, furmonertinib, and other novel therapeutics like next-generation antibody-drug conjugates through clinical development and commercialization, initially targeting solid tumors.

Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, focused on the early detection of cancer through innovative blood tests. Founded in 2018, the company employs artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in the blood, enabling the detection of previously unrecognized cancer-associated cell-free DNA fragments. By utilizing machine learning, Delfi Diagnostics aims to develop high-precision, non-invasive blood tests that allow healthcare professionals to detect cancer at its most curable stage, thereby facilitating timely and effective treatment options for patients.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

Frontera Therapeutics is a biotechnology company dedicated to developing and commercializing recombinant virus-based gene therapies. Its mission is to establish an affordable and scalable platform for producing high-quality rAAV therapies, targeting genetic disorders such as those affecting the eye, liver, metabolism, and neuromuscular systems.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells for the treatment of solid tumors. The company specializes in creating chimeric antigen receptor (CAR) T-cell therapies that target specific gene loss features in tumor cells, allowing for the selective destruction of cancerous tissues while preserving healthy ones. This technology aims to enhance tumor specificity, enabling the CAR-T cells to induce cytotoxicity only when engaging with tumor cells, thereby minimizing the safety risks commonly associated with existing CAR-T therapies. ImmPACT Bio's innovative approach seeks to improve treatment outcomes for cancer patients by offering a more precise and safer therapeutic option.

Beijing Tianxing is a clinical solutions company for sports medicine for implants, arthroscopy devices, and sports medicine equipment.

Founded in 2014, Cyrus Biotechnology develops software tools for accelerating basic research in biotech, pharma, and industrial biotechnology. Its flagship product, Cyrus Bench, offers an enterprise version of the Rosetta molecular modeling and design toolkit along with associated bio-molecular computation tools.

Acelyrin is a biopharmaceutical company dedicated to advancing treatments for diseases involving excessive immune system activation. It achieves this by discovering, acquiring, and expediting the development and market launch of innovative drug candidates.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

ADARx Pharmaceuticals specializes in the development of RNA editing therapeutics. Founded in 2019, the company focuses on discovering and developing innovative treatments that utilize endogenous enzymes to precisely target and correct single point mutations in mRNA transcripts, restoring the production of functional proteins.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company based in Campbell, California, focused on developing innovative therapies for gastrointestinal disorders. Incorporated in 2017, the company specializes in creating products that address unmet medical needs related to the enteric nervous system. One of its lead products, NG101, is designed to enhance gastric motility while also possessing antiemetic properties. Neurogastrx aims to provide effective solutions for functional and motility gastrointestinal disorders, targeting issues related to gut contractions, sensation, and the brain-gut axis, thereby addressing significant patient needs and alleviating disease burdens.

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing therapeutics that restore the function of microglia, the brain's immune cells. The company aims to improve outcomes for patients with neurodegenerative diseases by advancing its lead monoclonal antibody TREM2 agonist through Phase 1 trials and progressing its small molecule TREM2 agonist towards an Investigational New Drug (IND) application.

XinThera is a drug discovery company dedicated to developing precision medicines for the treatment of cancer and immunologic diseases. The company utilizes advanced computational chemistry technologies to design small molecule therapies aimed at well-validated targets that are often considered challenging in oncology and immunology. By focusing on these promising targets, XinThera strives to provide effective drug therapies that can address unmet medical needs for patients suffering from these conditions.

Zentera Therapeutics is a biopharmaceutical company.

Zion Pharma is a prominent drug discovery platform specializing in the development of innovative small molecule drugs, primarily targeting oncology and tumor treatment. The company is dedicated to creating "me-better" drugs that address significant unmet medical needs, with a particular emphasis on differentiated "best-in-class" and "first-in-class" therapies. Zion Pharma's innovative drug pipeline includes a focus on breast cancer brain metastasis, enabling healthcare professionals to better meet clinical demands and improve patient outcomes. Through its commitment to addressing critical issues in cancer treatment, Zion Pharma positions itself as a key player in the pharmaceutical industry.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Janux Therapeutics develops immunotherapies that target tumors without harming healthy tissue. Its proprietary technology enables two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr), designed to stimulate the immune system's response against cancer.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Founded in 2018, Scribe Therapeutics specializes in engineering and developing in vivo therapies based on CRISPR technology to rewrite and repair genetic disorders. Its proprietary platform, X-Editing (XE), enables greater efficacy, specificity, and deliverability compared to existing CRISPR technologies.

Graphite Bio is a clinical-stage gene editing company focused on targeted DNA integration to treat serious diseases. Its platform aims to precisely insert, repair, or replace genetic sequences by integrating therapeutic cargoes at predefined genomic locations, enabling correction of mutations or replacement of disease-causing genes while preserving normal regulatory control. Based in South San Francisco, the company pursues high-efficiency precision gene editing to address underlying causes of disease.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Founded in 2020 and headquartered in Boston, Massachusetts, Scorpion Therapeutics is a clinical-stage biotechnology company specializing in precision oncology. It develops targeted small-molecule drugs to treat cancer by focusing on three areas: therapies against known oncogenes, agents for currently undruggable targets, and drugs for new targets.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

BioNova Pharma biopharmaceutical company that develops and commercializes innovative medicines for cancer and other life-threatening diseases. The company is expanding company with a strong pipeline based on in-house R&D initiatives, partnerships with, and purchases from partners with cutting-edge technology. The goal of BioNova is to close the gap between the high unmet medical needs and the dearth of innovative medicines by developing an innovative R&D platform with a substantial pipeline to address multiple disease areas.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

ESCAPE Bio is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for genetically defined subpopulations affected by neurodegenerative diseases. Founded in 2015 and based in South San Francisco, California, the company aims to improve the lives of patients suffering from conditions such as Alzheimer's disease, Parkinson's disease, and sphingolipid storage disorders. ESCAPE Bio's pipeline includes innovative candidates like ESB1609, a small molecule S1P5 receptor agonist targeting CNS lysosomal storage disorders, and ESB5070, a kinase inhibitor specifically designed for Parkinson's patients with the LRRK2 G2019S variant. Additionally, the company is developing a program aimed at addressing the needs of Alzheimer's patients who carry the ApoE4 risk allele. Through its precision-targeted approach, ESCAPE Bio seeks to provide effective treatment options for individuals with these complex genetic profiles.

Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company's pipeline includes Naporafenib, ERAS-007, and ERAS-601, targeting various nodes of this pathway.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013, the company operates from its headquarters in Yantai, China, and has an additional office in Fremont, California. MabPlex provides a comprehensive range of services that encompass all stages of drug development, from DNA to finished drug products. Its offerings include customized mammalian cell medium, cell banking, and the manufacturing of monoclonal antibody active pharmaceutical ingredients, as well as fill and finish services for biologics and antibody-drug conjugates. The company aims to deliver high-quality solutions for bio-manufacturing to its global partners.

Norson Biotechnology produces edible probiotic powder, probiotic solid beverages, fermented lactic acid bacteria beverages, and other products.

AbCellera is an antibody discovery and development company that addresses conventional barriers to find optimal clinical candidates swiftly and efficiently. Its integrated platform combines diverse antibodies, expert selection, proprietary tools, and advanced data science to deliver developable leads quickly, setting partners up for long-term success.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Emendo Biotherapeutics is a biotechnology company focused on advancing genome editing technologies to develop genetic medicines. Established by a team of experts with backgrounds in protein engineering and DNA repair from prestigious institutions, Emendo aims to tackle the challenges associated with gene therapy. By innovating and transforming existing tools, the company seeks to address diseases and disorders that are presently deemed untreatable. Emendo's approach fuses diverse scientific disciplines with creative problem-solving, enabling the development of advanced gene editing solutions that enhance the efficacy of gene therapy and expand its potential applications. Through this commitment to pushing the boundaries of science, Emendo Biotherapeutics strives to fulfill the promise of gene editing for improved patient outcomes.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Repare Therapeutics is a precision oncology company that discovers and develops novel therapeutics using its synthetic lethality approach. It employs its proprietary SNIPRx platform to systematically identify and target genomic instability, particularly DNA damage repair pathways in cancer cells. The company's lead product candidate, RP-3500, is an oral small molecule inhibitor for treating solid tumors with specific DNA damage repair-related alterations.

Adicet Bio is a biotechnology company focused on developing off-the-shelf allogeneic gamma delta T cell therapies for cancer treatment. Its pipeline includes ADI-001, targeting CD20 for autoimmune diseases and B-cell lymphomas, and ADI-270, targeting renal cell carcinoma.

MDClone Ltd. is a company that specializes in software development for analyzing medical records. Founded in 2016 and based in Beersheba, Israel, MDClone has created a platform that generates synthetic medical records for fictitious patients, thus mitigating the risk of disclosing actual patient data. This innovative platform, known as ADAMS, provides a self-service analytics environment that facilitates exploration and collaboration across the healthcare ecosystem. By enabling researchers and healthcare organizations to examine disease behaviors, treatment efficacy, and operational efficiencies, MDClone supports the advancement of medical research and improves patient outcomes while ensuring the protection of sensitive medical information. The company serves a diverse clientele that includes major health systems, payers, and life sciences organizations in the United States, Canada, and Israel.

Prelude Therapeutics is a clinical-stage company developing novel, orally bioavailable small-molecule therapies to target critical pathways in cancer cell growth and resistance. Its pipeline includes four candidates in clinical development targeting MCL1, CDK9, CDK4/6, and SMARCA2/BRM proteins.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in developing radiopharmaceuticals as precision medicines. It focuses on creating targeted alpha therapeutics using its proprietary linker technology to enhance the safety and efficacy of these drugs, ultimately improving cancer patient outcomes.

Laekna Therapeutics is a clinical‑stage biotechnology company that develops novel therapies for oncology and liver disease. The company has built a comprehensive research and development platform that moves molecules from discovery to registration‑ready trials. It has initiated six clinical studies, including three multi‑regional trials targeting standard‑of‑care resistant cancers. Its lead product candidates are LAE002, an ATP‑competitive AKT inhibitor for ovarian cancer, and LAE001, a therapeutic agent for liver disease. Laekna also maintains a broader pipeline of 14 additional candidates.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Apollomics is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies that harness the immune system and target specific cancer signaling pathways. Founded in 2016 and headquartered in Foster City, California, the company develops monoclonal antibodies and targeted small molecules aimed at immune checkpoints and dysregulated growth pathways, with a portfolio that includes anti-PD-1 and anti-PD-L1 antibodies and inhibitors affecting EMT and MAPK signaling. Apollomics aims to advance monotherapy and combination regimens designed to enhance anti-tumor immune responses and inhibit tumor growth.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that focuses on discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is currently undergoing Phase 2 clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is developing NC410, designed to inhibit immune suppression through the modulation of a specific immune receptor. The company is also advancing other product candidates, including LNCB74, an antibody-drug conjugate targeting B7-H4, and is exploring additional immunomodulatory molecules in preclinical stages. NextCure has established collaborations with Yale University for licensing and with Eli Lilly and Company for research and development. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets in its pursuit of first-in-class immunotherapy solutions.

Founded in 2017, Terns Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing molecularly targeted, oral small-molecule drugs for treating cancer and liver diseases. Headquartered in Foster City, California with offices in Shanghai, China, the company focuses on advancing its pipeline of drugs optimized against clinically validated targets.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

SmartZyme Biopharma is a medical technology company focused on enhancing continuous glucose monitoring (CGM) for individuals with diabetes. It specializes in integrating its next-generation glucose-sensing enzyme into CGM devices, aiming to improve performance, safety, and user experience. Unlike traditional methods, SmartZyme's enzyme eliminates the need for signal mediators, reducing manufacturing costs; minimizes hypoglycemic errors, ensuring superior safety; and eliminates fingersticks, enhancing quality of life. The company is backed by OrbiMed, a leading healthcare investment firm.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

Pionyr Immunotherapeutics Inc. is a biotechnology company focused on developing innovative cancer immunotherapies that specifically target the tumor microenvironment to enhance the body's antitumor immunity. Founded in 2015 and based in San Francisco, California, Pionyr leverages advanced target discovery and antibody generation platform technologies to create next-generation immuno-oncology therapeutics. The company's proprietary approach, known as Myeloid Tuning™, aims to improve the immune system’s anti-tumor response by precisely altering the cellular composition within the tumor microenvironment. This strategy is designed to enable patients to better combat cancer, particularly when used in conjunction with checkpoint inhibitors.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

RDD Pharma, Ltd. is a pharmaceutical company based in Tel-Aviv, Israel, with an additional office in New York, New York. Founded in 2008, RDD Pharma focuses on the development and commercialization of targeted therapeutics for anorectal diseases and gastrointestinal disorders. The company specializes in creating innovative pharmacological treatments for conditions such as chronic anal fissures, fecal incontinence, and pruritus ani, particularly in patients with spinal cord injuries. RDD Pharma addresses the unique challenges of treating these conditions by employing specialized formulation and delivery techniques that cater to the anatomical and physiological variations in this sensitive area.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). The company aims to address the root causes of MGD and other ocular surface diseases through a diverse portfolio of compounds and a novel drug delivery platform. By enhancing treatment options in a field where choices are currently limited, Azura seeks to improve the health and well-being of millions affected by these conditions. Headquartered in Tel Aviv-Yafo, Israel, Azura also operates in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of ocular treatments.

MobileODT develops optical diagnostic devices and software for early cancer detection, enabling health care providers to perform visual examinations with portable, internet-connected tools. The Enhanced Visual Assessment system includes the FDA-cleared EVA COLPO portable colposcope and accompanying software to securely store and manage patient data via HIPAA-compliant cloud services such as EVA SANE, and a digital visualization tool for gynecologic exams, EVA WELL. The company also offers a portfolio of aids for screening, including a mobile app for Android that enables remote image capture and patient information tracking, an online portal for collaboration and reporting, and cloud storage solutions for documented patient data. Founded in 2012 and based in Tel Aviv with an additional location in New York, MobileODT aims to extend expert-level diagnostic capabilities to diverse healthcare settings and geographies, including applications in cervical cancer screening and other visual-based diagnostics.

LogicBio Therapeutics, Inc. is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly for pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology platform, LogicBio aims to integrate corrective genes into patients' genomes to achieve therapeutic effects. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a serious condition that manifests at birth. Additionally, LogicBio is advancing other product candidates, including LB-101 and LB-301, the latter developed in collaboration with Takeda Pharmaceutical Company to address Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors, enhancing the potential of its gene therapy approaches. Founded in 2014, LogicBio is headquartered in Lexington, Massachusetts.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company has developed a range of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Among its notable products is D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in creating targeted immuno-oncology therapies that can be used in combination with existing treatments, such as PD-1 antibodies, to address various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with extensive experience in drug discovery at major pharmaceutical companies, InventisBio aims to provide effective therapies for significant health challenges.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.